Hims & Hers Health, Inc. (HIMS)
| Market Cap | 7.78B |
| Revenue (ttm) | 1.48B |
| Net Income (ttm) | 126.04M |
| Shares Out | 222.17M |
| EPS (ttm) | 0.53 |
| PE Ratio | 65.84 |
| Forward PE | 54.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,176,234 |
| Open | 37.94 |
| Previous Close | 28.48 |
| Day's Range | 32.95 - 37.94 |
| 52-Week Range | 11.20 - 72.98 |
| Beta | 1.65 |
| Analysts | Hold |
| Price Target | 36.92 (+5.37%) |
| Earnings Date | May 5, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price forecast is $36.92, which is an increase of 5.37% from the latest price.
News
Hims & Hers Health: GLP-1 Deals De-Risk The Story
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness pla...
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/mon...
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the l...
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Hims & Hers Health (HIMS) stock surges 34% on partnership with Novo Nordisk to sell Wegovy
Shares of Hims & Hers Health soared more than 34% in premarket trading on Tuesday after Novo Nordisk announced a partnership with the telehealth company to expand access to its popular weight loss dru...
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.
The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many comp...
Hims & Hers partners with Novo Nordisk to sell Wegovy on its platform
Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled offering on the telehealth company's platform, the two companies said on Tu...
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, mo...
Hims & Hers: Selling Options On This High-Growth Gem Could Yield 20% Or More (Rating Upgrade)
Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put option...
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufactur...
Hims & Hers: Top Pick For The Next Decade
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization...
Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom, Analysts Say
Investors worry patients won't make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
Hims & Hers Expands Weight Loss Offering, Adds Lilly's Zepbound to Platform
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers shares rise as company adds new weight-loss medications to platform
Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have e...
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
Here's why Hims & Hers stock price has crashed: buy the dip?
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from i...
Hims & Hers Health: Reaching Escape Velocity Goes Unnoticed By The Market
I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stoc...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and wome...
Hims & Hers Health: Developing A Better Understanding
Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a un...
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted ...